Our Strategic Vision

The Company’s strategic focus is to accelerate penetration of acute pain portfolio through expansion into new customer channels and geography, and to grow its Respiratory segment through market share gains. The clinical hold lifted by the FDA without any additional conditions has allowed commencement of Phase III clinical trials for our acute pain portfolio, which has opened the door for longer-term growth in the USA.